2.71
Schlusskurs vom Vortag:
$2.57
Offen:
$2.63
24-Stunden-Volumen:
292.00K
Relative Volume:
1.19
Marktkapitalisierung:
$121.42M
Einnahmen:
$8,000
Nettoeinkommen (Verlust:
$-32.15M
KGV:
-3.1293
EPS:
-0.866
Netto-Cashflow:
$-26.37M
1W Leistung:
+17.83%
1M Leistung:
+0.00%
6M Leistung:
-40.31%
1J Leistung:
+13.39%
Genelux Corp Stock (GNLX) Company Profile
Firmenname
Genelux Corp
Sektor
Branche
Telefon
805-267-9889
Adresse
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
GNLX
Genelux Corp
|
2.71 | 115.15M | 8,000 | -32.15M | -26.37M | -0.866 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.56 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.84 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.14 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.59 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
163.86 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Lake Street | Buy |
| 2024-10-29 | Eingeleitet | Guggenheim | Buy |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-09-12 | Eingeleitet | Maxim Group | Buy |
| 2023-02-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Alle ansehen
Genelux Corp Aktie (GNLX) Neueste Nachrichten
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
GNLX Technical Analysis & Stock Price Forecast - Intellectia AI
Analyst Calls: Can Genelux Corporation outperform in the next rally2026 Market Outlook & AI Driven Price Predictions - baoquankhu1.vn
GNLX PE Ratio & Valuation, Is GNLX Overvalued - Intellectia AI
Cappello, Genelux CTO, sells $2192 in GNLX stock By Investing.com - Investing.com Australia
Genelux head of regulatory sells $1.4k in shares By Investing.com - Investing.com Australia
Yu Yong, Genelux SVP, sells $2192 in GNLX stock By Investing.com - in.investing.com
Genelux CEO Zindrick sells $8668 in shares By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $1.4k in shares - investing.com
Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com
Genelux CEO Zindrick sells $8668 in shares - Investing.com
Genelux (GNLX) Head of Regulatory sells 585 shares to cover RSU taxes - Stock Titan
[Form 4] GENELUX Corp Insider Trading Activity - Stock Titan
Genelux (NASDAQ: GNLX) SVP sells 906 shares to cover RSU taxes - Stock Titan
Genelux (GNLX) CEO sells shares to cover RSU tax obligations - Stock Titan
AI Stocks: Is Genelux Corporation showing insider buyingShort Setup & Technical Pattern Alert System - baoquankhu1.vn
FY2029 Earnings Estimate for Genelux Issued By HC Wainwright - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Genelux (NASDAQ:GNLX) Price Target Cut to $20.00 by Analysts at Benchmark - MarketBeat
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside - TipRanks
Genelux Corp 2024 Annual Report: Oncolytic Virus Pipeline, Olvi-Vec Clinical Trials, Strategy, Risks, and Competitive Landscape 66686970719293 - Minichart
Gap Down: Can Genelux Corporation be recession proof2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Genelux (NASDAQ: GNLX) launches $100M at-the-market program with TD Cowen - Stock Titan
Genelux Establishes $100 Million At-The-Market Equity Program - TipRanks
Genelux Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Genelux Establishes $100 Million ATM Equity Program With TD Cowen - TradingView
Genelux (NASDAQ: GNLX) launches $100M at-the-market stock plan - stocktitan.net
Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment - Quiver Quantitative
[10-K] GENELUX Corp Files Annual Report | GNLX SEC FilingForm 10-K - Stock Titan
GENELUX 2025 10-K: Revenue $0.01M, Net Loss $32.1M - tradingview.com
Cancer drug readout nears as Genelux says cash lasts into 2027 - Stock Titan
Aug Analyst Calls: What is the long term forecast for Genelux Corporation stockMarket Trend Review & Free Verified High Yield Trade Plans - baoquankhu1.vn
Genelux Corp. (GNLX) Gets a Buy from Maxim Group - The Globe and Mail
Genelux Corp expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock - MarketBeat
[144] GENELUX Corp SEC Filing - Stock Titan
GNLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GNLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Genelux Corporation outperform in the next rallyJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Genelux Corporation to Participate in Upcoming Conferences - Yahoo Finance
8.2% Genelux (NASDAQ: GNLX) stake disclosed by holder Aladar Szalay - Stock Titan
Will Genelux Corporation stock continue dividend increasesMarket Activity Report & Safe Capital Growth Tips - mfd.ru
Genelux Updates Corporate Presentation for Investors and Stakeholders - The Globe and Mail
US Stocks Recap: Is Outlook Therapeutics Inc stock good for income investorsM&A Rumor & Safe Capital Growth Plans - baoquankhu1.vn
Genelux appoints Jason Litten as CMO - MSN
Brokers Offer Predictions for Genelux Q1 Earnings - Defense World
Aug Sectors: Will Genelux Corporation benefit from AI trendsExit Point & High Yield Stock Recommendations - baoquankhu1.vn
Aug Momentum: Will Genelux Corporation benefit from AI trendsRate Hike & Smart Money Movement Tracker - baoquankhu1.vn
Finanzdaten der Genelux Corp-Aktie (GNLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genelux Corp-Aktie (GNLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Smalling Ralph | Head of Regulatory |
Mar 25 '26 |
Sale |
2.51 |
240 |
602 |
68,073 |
| Cappello Joseph | Chief Technical Officer |
Mar 24 '26 |
Sale |
2.42 |
906 |
2,193 |
155,154 |
| Yu Yong | SVP, Clinical Development |
Mar 24 '26 |
Sale |
2.42 |
906 |
2,193 |
144,938 |
| Zindrick Thomas | President and CEO |
Mar 24 '26 |
Sale |
2.42 |
3,582 |
8,668 |
534,849 |
| Thomas John | Director |
Mar 02 '26 |
Sale |
2.90 |
10,000 |
28,957 |
482,784 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):